Cereno Scientific applies for a patent for CS014

Report this content

Cereno Scientific announced today that the company has applied for a patent for the compound CS014 (previously called EB014) in order to further strengthen the company’s patent portfolio.

Cereno Scientific is developing preventive medicines to treat cardiovascular diseases. The company’s drug candidate CS1 has demonstrated positive results in both pre-clinical and clinical studies and Cereno Scientific is now preparing for a Phase II study. Aiming at further strengthening Cereno Scientific’s pipeline, the company acquired the compound CS014 from Emeriti Bio AB in March 2019. The compound is in the pre-clinical stage and has promising and innovative characteristics. The patent application protects the compound CS014, the related compound family and their use regarding a variety of different cardiovascular diseases.

“We have intensified our work to strengthen our intellectual property rights to ensure the future market potential of our drug candidates. We have previously acquired patents for our first drug candidate CS1 on strategic important markets and it’s very positive that we have applied for the first patent for our newly acquired compound CS014, which significantly increases the potential of the value development of our portfolio”, says Cereno Scientific’s CEO Sten R. Sörensen.

The development of CS014 is being done in collaboration with Emeriti Bio AB. The collaboration was initiated immediately after the acquisition of the compound and proceeds according to plan.

For further information, please contact:
Sten R. Sörensen – CEO
Tel: +46 733 74 03 74
E-mail: sten.sorensen@cerenoscientific.com

About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. In parallel with the development of CS1, Cereno Scientific develops CS014, a preclinical phase compound with promising and innovative characteristics in cardiovascular diseases. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558. 


Documents & Links